Special Section: Autologous Stem Cell Tranplantations in Solid Tumours: Autologous Stem Cell Transplants in Lymphomas

References

• Longo D L, Young R C, Wesley M, Hubard S M, DeVita V J. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986; 4: 1295
   PubMed Web of Science ®Google Scholar
• Prosnitz L R, Farber L R, Kapp D S. Combined modality therapy for advanced Hodgkin's disease: 15 year follow-up data. J Clin Oncol 1988; 6: 603
   PubMed Web of Science ®Google Scholar
• Canellos G P, Young R C, DeVita V T. Combination chemotherapy for advanced Hodgkin's disease in relapse following extensive radiotherapy. Clin Pharmacol Ther 1972; 13: 75
   Google Scholar
• Bonnadonna G, Santoro A, Gianni A M, et al. Primary and salvage chemotherapy in advanced Hodgkin's disease: The Milan Cancer Institute experience. Ann Oncol 1991; 1: 9
   Google Scholar
• Chopra R, Mc Millan A K, Linch D C, et al. The place of high dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single centre eight year study of 155 patients. Blood 1993; 81: 1137–45
   PubMed Web of Science ®Google Scholar
• Zulian G B, Selby P, Milan S, et al. High dose melphalan, BCNU, and etoposide with autologous bone marrow transplantation for Hodgkin's disease. Br J Cancer 1989; 59: 63
   Google Scholar
• Carella A M, Congiu A M, Gaozza E, et al. High dose chemotherapy and autologous bone marrow transplantation in 50 advanced resistant Hodgkin's patients: an Italian study group report. J Clin Oncol 1988; 6: 1411
   PubMed Web of Science ®Google Scholar
• Jagannath S, Armitage J O, Dicke K, et al. Prognostic factors for response and survival after high dose cyclophosphamide, carmustine and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1989; 7: 179
   PubMed Web of Science ®Google Scholar
• Reece D C, Barnett M J, Connors J M, et al. Intensive chemotherapy with cyclophosphamide, carmustine and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1991; 9: 1871
   PubMed Web of Science ®Google Scholar
• Linch D C, Winfield D, Goldstone A H, et al. Dose intensification with autologous bone marrow rescue in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051–4
   PubMed Web of Science ®Google Scholar
• Mc Millan A K, Goldstone A H. What is the value of autologous bone marrow transplantation in the treatment of relapsed or resistant Hodgkin's disease. Leuk Res 1991; 15: 237–43
   PubMed Web of Science ®Google Scholar
• Carella A M. Indications for autologous bone marrow transplantation in Hodgkin's disease. Leuk Lymphoma 1992; 7: 21–2
   PubMed Web of Science ®Google Scholar
• Carey P, Procter S J, Taylor P, et al. Autologous bone marrow transplantation for high grade malignancy using melphalan/irradiation conditioning without marrow purging or cryopreservation. Blood 1991; 77: 1593–8
   PubMed Web of Science ®Google Scholar
• Fisher Rl, Gaynor E R, Dahlberg S, et al. Comparison of a standard regimen CHOP with three intensive chemotherapy regimens for advanced non Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–6
   PubMed Web of Science ®Google Scholar
• Gordon L I, Harrington D, Andersen J, et al. Comparison of a second generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992; 327: 1342–9
   PubMed Web of Science ®Google Scholar
• Singer C R, Goldstone A H. Clinical studies in ABMT in non-Hodgkin's lymphoma. Clin Haematol 1986; 15: 105–50
   PubMedGoogle Scholar
• Mills W, Chopra R, Mc Millan A, Pearce R, Linch D C, Goldstone A H. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 588–95
   PubMed Web of Science ®Google Scholar
• Vose J M, Armitage J O, Bierman P J, et al. Salvage therapy for relapsed or refractory non Hodgkin's lymphoma utilising autologous bone marrow transplantation. Am J Med 1989; 87: 285–8
   PubMed Web of Science ®Google Scholar
• Philip T, Armitage J O, Spitzer G, et al. High dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987; 316: 1493–8
   PubMed Web of Science ®Google Scholar
• Colombat P, Gorin N C, Lemmonier M P, et al. The role of autologous bone marrow transplantation in 46 adult patients with non Hodgkin's lymphoma. J Clin Oncol 1990; 8: 630–7
   PubMed Web of Science ®Google Scholar
• Hurd D D, Le Bien T W, Lasky L D, et al. Autologous bone marrow transplantation in non-Hodgkin's lymphoma. Am J Med 1988; 85: 829–34
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation vs. salvage chemotherapy in relapsed chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540
   PubMed Web of Science ®Google Scholar
• Majolino I, Pearce R, Taghipour G, Goldstone A H. PBSCT vs. ABMT in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the EBMT Registry data, submitted
   Google Scholar
• Verdonck L F, van Putten W, Hagenbeek A, et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 1995; 332: 1045–51
   PubMed Web of Science ®Google Scholar
• Haioun C, Lepage E, Gisselbrecht C, et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non Hodgkin's lymphoma in first complete remission: a study of 464 patients. J Clin Oncol 1994; 12: 2543–51
   PubMed Web of Science ®Google Scholar
• Rohatiner A Z, Lister A T. New approaches to the treatment of follicular lymphoma. Br J Haematol 1991; 79: 349–54
   PubMedGoogle Scholar
• Freedman A S, Ritz J, Neuberg D. Autologous bone marrow transplantation in 69 patients with a history of low grade B cell non-Hodgkin's lymphoma. Blood 1991; 77: 2524–9
   PubMed Web of Science ®Google Scholar
• Gribben J G, Freedman A S, Neuberg D, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991; 325: 1525
   PubMed Web of Science ®Google Scholar
• Price C G, Rohatiner A Z, Cotter F E, et al. Minimal residual disease and the efficacy of in vitro bone marrow purging in follicular lymphoma measured by an adapted polymerase chain reaction (PCR) technique. Proc Am Soc Clin Oncol 1990; 9, Abstract 999
   Google Scholar
• Cooper M. B-lymphocytes, normal development and function. N Eng J Med 1987; 317: 1452
   PubMed Web of Science ®Google Scholar
• Till J E, McCulloch E A. A direct measurement of the radiation sensitivity of normal bone marrow cells. Radiat Res 1961; 14: 213–22
   PubMed Web of Science ®Google Scholar
• Muller Sieburg C E, Townsend K, Weissman I L, Rennick D. Proliferation and differentiation of highly enriched mouse hematopoietic stem cells and progenitor cells in response to defined growth factors. J Exp Med 1988; 167: 1825–40
   PubMedGoogle Scholar
• Sutherland H J, Eaves C J, Eaves A C, Dragowska W, Lansdorp P M. Characterization and partial purification of human marrow cells capable of initiating long-term haematopoiesis in vitro. Blood 1989; 77: 2122–8
   Google Scholar
• Spitzer G, Verma D S, Fisher R, et al. The myeloid progenitor cell - its value in predicting hematopoietic recovery after autologous bone marrow transplantation. Blood 1980; 55: 317–23
   PubMed Web of Science ®Google Scholar
• Civin Cl, Trischmann T M, Fackler M J. Report on the CD34 cluster workshops. Leukocyte Typing IV: White Cell Differentiation Antigens, W Knapp, B Dorken, W R Gilks, et al. Oxford University Press, Oxford 1988; 818–25
   Google Scholar
• Bertoncello I, Bradley T R, Hodgson G S, Dunlop J M. The resolution, enrichment and organization of normal bone marrow high proliferative potential colony forming subsets on the basis of rhodamine 123 fluorescence. Exp Hematol 1991; 174–8
   PubMedGoogle Scholar
• Andrews R G, Singer J W, Bernstein I D. Human haematopoietic precursors in long term culture: single CD34 + cells that lack detectable T cell, B cell and myeloid cell antigens produce multiple colony forming cells when cultured with marrow stromal cells. J Exp Med 1990; 172: 355–8
   PubMed Web of Science ®Google Scholar
• Bender J G, Unverzagt K L, Walker D E, et al. Identification and comparison of CD34 positive cells and their subpopulations from normal peripheral blood and bone marrow using multicolour flow cytometry. Blood 1991; 77: 2591–6
   PubMed Web of Science ®Google Scholar
• Siena S, Bregni M, Brando B, et al. Flow cytometry for the clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1991; 77: 400–9
   PubMed Web of Science ®Google Scholar
• Siena S, Bregni M, Belli N, et al. Practical aspects of flow cytometry to guide large scale collection of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Int J Cell Cloning 1992; 10: 26–9
   Google Scholar
• Goodman J W, Hodgson G S. Evidence for stem cells in the peripheral blood of mice. Blood 1962; 19: 702–14
   PubMed Web of Science ®Google Scholar
• Cavins J A, Scheer S C, Thomas E D, Ferrebee J W. The recovery of lethally irradiated dogs given infusions of autologous leukocytes preserved at —80C. Blood 1964; 23: 38–43
   PubMed Web of Science ®Google Scholar
• Northdruft W, Bruch C, Fliedner T M, Ruper E. Studies on the regeneration of the CFU-C population in blood and bone marrow of lethally irradiated dogs after autologous transfusion of cryopreserved mononuclear blood cells. Scand J Haematol 1977; 19: 470–81
   PubMedGoogle Scholar
• Abrams R A, Mc Cormack K, Bowles C, Deisseroth A B. Cyclophosphamide treatment expands the circulating hematopoietic stem cell pool in dogs. J Clin Invest 1981; 67: 1392–9
   PubMed Web of Science ®Google Scholar
• Craig J O, Turner M L, Parker A C. Peripheral blood stem cell transplantation. Blood Rev 1992; 6: 59–67
   PubMedGoogle Scholar
• Chervenick P A. Increase in circulating stem cells in patients with myelofibrosis. Blood 1973; 41: 67–71
   PubMed Web of Science ®Google Scholar
• Hibben J A, Nloku O S, Matutes E, Lewis S M, Goldman J M. Myeloid progenitor cells in the circulation of patients with myelofibrosis and other myeloproliferative disorders. Br J Haematol 1984; 47: 1031–9
   Google Scholar
• To L B, Haylock L B, Kimber R J, Juttner J A. High levels of circulating haematopoietic stem cells in very early remission from acute non-lymphoblastic leukaemia and their collection and cryopreservation. Br J Haematol 1984; 58: 399–410
   PubMed Web of Science ®Google Scholar
• Reid C D, Kirk A, Muir J, Chanarin I. The recovery of circulating progenitor after chemotherapy in AML and ALL and its relation to the rate of bone marrow regeneration after aplasia. Br J Haematol 1989; 72: 21–7
   PubMed Web of Science ®Google Scholar
• Wunder E, Sovalat H, Liang H, Eisenmann J C, Henon P. Mobilization of peripheral stem cells after high dose chemotherapy in multiple myeloma. Int J Cell Cloning 1992; 10: 38–40
   Google Scholar
• Sheridan W P, Begley C J, Juttner C A, et al. G-CSF mobilized peripheral and autologous bone marrow infusion following high dose chemotherapy. Int J Cell Cloning 1982; 10: 71–3
   Google Scholar
• Socinski M A, Cannistra S A, Elias A, Antman K H, Schipper L, Griffen J D. Granulocyte macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988; II: 1194–8
   Google Scholar
• Ganser A, Lindemann A, Seipelt G, et al. Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure. Blood 1990; 76: 666–76
   PubMed Web of Science ®Google Scholar
• To L B, Davy M L, Haylock D N, Dyson D J, Thorp D, Juttner C A. Autotransplantation using peripheral blood stem cells mobilised by cyclophosphamide. Bone Marrow Transplant 1989; 4: 595–6
   PubMed Web of Science ®Google Scholar
• Pettengel R, Demuynck H, Testa N G, Dexter T M. The engraftment capacity of peripheral blood progenitor cells mobilised with chemotherapy +/-G-CSF. Int J Cell Cloning 1992; 10: 59–61
   Google Scholar
• Jones H M, Jones S A, Watts M J, et al. Development of a simplified single apheresis approach for peripheral blood progenitor cell transplantation in previously treated patients with lymphoma. J Clin Oncol 1994; 12: 1693–702
   PubMed Web of Science ®Google Scholar
• To L B, Haylock D N, Dyson D J. A comparison between 4 gms/m2 and 7 gms/m2 cyclophospahmide from peripheral blood stem cell mobilization. Int J Cell Cloning 1992; 10: 33–4
   PubMedGoogle Scholar
• Kotasek D, Shepherd K M, Sage R E, et al. Factors affecting blood stem cell collections following high dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumours. Bone Marrow Transplant 1992; 9: 11–7
   PubMed Web of Science ®Google Scholar
• Russell N H, Hunter A, Rogers S, Hanley J, Anderson D. Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation (Letter). Lancet 1993; 341: 1482
   PubMed Web of Science ®Google Scholar
• Champlin R. Preperative regimens for autologous bone marrow transplantation. Blood 1993; 81: 277–80
   PubMed Web of Science ®Google Scholar
• Jagannath S, Dicke K A, Armitage J O, et al. High dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann Intern Med 1986; 104: 163
   PubMed Web of Science ®Google Scholar
• Wilson W H, Jain V, Bryant G, et al. Phase I and II study of high dose Ifosfamide, Carboplatin and Etoposide with autologous bone marrow rescue in lymphomas and solid tumours. J Clin Oncol 1992; 10: 1712–22
   PubMed Web of Science ®Google Scholar
• Lazarus H M, Crilley R, Ciobanu N. High dose carmustine, etoposide and cisplatinum and autologous bone marrow transplantation for relapsed and refractory lymphoma. J Clin Oncol 1992; 10: 1712–22
   PubMedGoogle Scholar
• Armitage J O. Bone marrow transplantation in the treatment of patients with lymphoma. Blood 1989; 73: 1749–58
   PubMed Web of Science ®Google Scholar
• Sheridan W P, Morstyn G, Wolf M, et al. Granulocyte colony-stimulating factor and neutrophil recovery after high dose chemotherapy and autologous bone marrow transplantation. Lancet 1989; II: 891–5
   Google Scholar
• Korbling M, Martin H. Transplantation of hemapheresis derived hemopoietic stem cells; a new concept in the treatment of patients with malignant lymphohemopoietic disorders. Plasma Ther Transfus Technol 1988; 9: 119–32
   Google Scholar
• Bell A J, Oscier D J, Figes A, Hamblin T J. Use of circulating stem cells to accelerate myeloid recovery after autologous bone marrow transplantation. Br J Haematol 1987; 67: 252–3
   PubMedGoogle Scholar
• Bregni M, Magni M, Siena S, et al. Human peripheral blood hematopoietic progenitors are optimal targets of retroviral-mediated gene transfer. Blood 1992; 80: 1418–22
   PubMed Web of Science ®Google Scholar
• Cassel A, Cottier-Fox M, Doren S, Dunbar C E. Retroviral mediated gene transfer into CD34+ve enriched human peripheral blood stem cells. Exp Hematol 1993; 21: 585–91
   PubMed Web of Science ®Google Scholar
• Blaese R M, Culvert Chang K W, et al. Treatment of severe combined immunodeficiency disease due to adenine deaminase deficiency with CD34 + selected autologous peripheral blood cells transduced into a human ADA gene. Hum Gene Ther 1993; 4: 521–7
   PubMed Web of Science ®Google Scholar
• Brenner M K, Rill D R, Moen R C, et al. Gene marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85–6
   PubMed Web of Science ®Google Scholar
• Heimfeld S, Colter M A, Corpuz S R, Stray K M, Berenson R J. Combination of Ceprate CD34+ column selection followed by a second avidin-biotin negative depletion results in enhanced purging of tumour cells or B-cells. Blood 1993; 82: 2578, Suppl
   Google Scholar
• Mayani H, Dragowski W, Lansdorp P M. Characterization of functionally distinct subpopulations of CD34 cord blood cells in serum-free long-term cultures supplemented with hematopoietic cytokines. Blood 1993; 82: 2664–72
   PubMed Web of Science ®Google Scholar
• Sato N, Sawadi K, Koizumi K, et al. In vitro expansion of human peripheral blood CD34 cells. Blood 1993; 82: 3600–9
   PubMed Web of Science ®Google Scholar